Derma-Smoothe/Fs

Otitis Externa, Uveitis, Perianal erythema + 30 more

Treatment

3 FDA approvals

20 Active Studies for Derma-Smoothe/Fs

What is Derma-Smoothe/Fs

Fluocinolone acetonide

The Generic name of this drug

Treatment Summary

Fluocinolone acetonide is a type of corticosteroid medication with a high fat solubility. It is used in topical skin creams and has also been studied for use in implantable corticosteroid devices. The FDA approved the use of this drug in implantable devices in 2016.

Neo-Synalar

is the brand name

image of different drug pills on a surface

Derma-Smoothe/Fs Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Neo-Synalar

Fluocinolone acetonide

1963

93

Approved as Treatment by the FDA

Fluocinolone acetonide, otherwise called Neo-Synalar, is approved by the FDA for 3 uses like Chronic Uveitis and Uveitis .

Chronic Uveitis

Uveitis

Uveitis

Effectiveness

How Derma-Smoothe/Fs Affects Patients

Fluocinolone acetonide is a medication used to reduce inflammation. When used in the eyes, it comes in the form of a small implant. Studies have found that the implant can reduce the recurrence of uveitis flares by two times compared to those without the implant, even after six months. It can also increase the pressure inside the eye slightly, so it is important to monitor this closely.

How Derma-Smoothe/Fs works in the body

Fluocinolone acetonide is a corticosteroid that reduces inflammation by binding to the glucocorticoid receptor. This triggers a reaction that causes the cell to produce proteins called lipocortins, which block the release of arachidonic acid. This is a precursor for inflammation-causing molecules like prostaglandins and leukotrienes. By blocking these molecules, fluocinolone can reduce inflammation.

When to interrupt dosage

The proffered dosage of Derma-Smoothe/Fs is contingent upon the identified condition, for example Hemorrhoids, Perianal erythema and Itch. The magnitude of dosage relies upon the method of delivery (e.g. Kit or Emulsion - Topical) outlined in the table beneath.

Condition

Dosage

Administration

Pressure Ulcer

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Conjunctivitis, Bacterial

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin Inflammation caused by Bacterial Infections

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Diabetic Macular Edema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Postoperative Care

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Eczema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Dermatitis, Seborrheic

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Externa

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Media

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Chronic disease

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Surgery; Ear

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

postoperative treatment

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Ear structure

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Wound Infection

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Perianal erythema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Scab

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Itching

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Warnings

Derma-Smoothe/Fs Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

Mycoses

Do Not Combine

External auditory canal structure

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

There are 20 known major drug interactions with Derma-Smoothe/Fs.

Common Derma-Smoothe/Fs Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Fluocinolone acetonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abetimus.

Derma-Smoothe/Fs Toxicity & Overdose Risk

There have been no studies to determine if fluocinolone acetonide can cause cancer or harm fertility. However, other corticosteroid drugs have been found to be genotoxic, though fluocinolone acetonide was not found to be genotoxic in two tests.

Derma-Smoothe/Fs Novel Uses: Which Conditions Have a Clinical Trial Featuring Derma-Smoothe/Fs?

97 active clinical trials are exploring the potential of Derma-Smoothe/Fs to treat Atopic Dermatitis, Otitis Media and Otitis Externa.

Condition

Clinical Trials

Trial Phases

Hemorrhoids

1 Actively Recruiting

Not Applicable

Perianal erythema

0 Actively Recruiting

Eczema

0 Actively Recruiting

Blister

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

Psoriasis of the scalp

1 Actively Recruiting

Phase 4

Otitis

3 Actively Recruiting

Not Applicable

Hemorrhoids

0 Actively Recruiting

Scab

0 Actively Recruiting

Ear structure

0 Actively Recruiting

Skin

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

Fissure in Ano

0 Actively Recruiting

Postoperative Care

5 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable

Wound Infection

0 Actively Recruiting

Skin Inflammation caused by Bacterial Infections

0 Actively Recruiting

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Conjunctivitis, Bacterial

0 Actively Recruiting

Coinfection

0 Actively Recruiting

Chronic disease

0 Actively Recruiting

Derma-Smoothe/Fs Reviews: What are patients saying about Derma-Smoothe/Fs?

5

Patient Review

12/22/2008

Derma-Smoothe/Fs for Atopic Dermatitis

My daughter's eczema has been a huge problem since birth, and we've tried everything. This oil is like a miracle drug; she was 97% cleared up within just three days of using it. I also put aquaphor on after the oil, and she's like a new child.

2

Patient Review

2/11/2009

Derma-Smoothe/Fs for Psoriasis of Scalp

I started to experience bad headaches after only two days of use. When I told my doctor, he prescribed me a different medication.

Patient Q&A Section about derma-smoothe/fs

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you use Derma smoothe on face?

"This product should not be used on the face, under the arms, or in the groin area unless specifically directed by a physician. Applying it to areas where skin rubs together should be avoided as it increases the risk of local adverse reactions."

Answered by AI

Is Derma smoothe a steroid?

"Is Flucinolone effective in reducing inflammation, redness, and itchiness caused by eczema and scalp psoriasis?"

Answered by AI

Do you need a prescription for Derma smoothe?

"Derma-Smoothe FS is a prescription medication that is used to alleviate the symptoms associated with eczema. It can be used by itself or in conjunction with other medications."

Answered by AI

What is Derma Smoothe FS body oil used for?

"This medication is used to treat eczema, a skin condition marked by red, irritated, and itchy skin. Fluocinolone reduces these symptoms by working as a low- to medium-strength corticosteroid."

Answered by AI

Clinical Trials for Derma-Smoothe/Fs

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of University of California, Los Angeles in Los Angeles, United States.

Hemorrhoidal Artery Embolization for Hemorrhoids

18 - 90
All Sexes
Los Angeles, CA

Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.

Recruiting
Has No Placebo

University of California, Los Angeles

Lucas Cusumano, MD

Have you considered Derma-Smoothe/Fs clinical trials?

We made a collection of clinical trials featuring Derma-Smoothe/Fs, we think they might fit your search criteria.
Go to Trials
Image of The University of Alabama at Birmingham in Birmingham, United States.

Octreotide for Diabetic Macular Edema

18 - 90
All Sexes
Birmingham, AL

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential therapeutic benefits in proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). This study thus seeks to determine the efficacy and safety of intranasal DDM-octreotide in the treatment of diabetic macula edema in individuals that are considered to be refractory to the current therapeutic options.

Phase 1
Waitlist Available

The University of Alabama at Birmingham

Maria Grant, MD, FARVO

Image of Associated Retinal Consultants PC in Phoenix, United States.

RO7446603 + Aflibercept/Faricimab for Diabetic Macular Edema

18+
All Sexes
Phoenix, AZ

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

Phase 1 & 2
Recruiting

Associated Retinal Consultants PC (+70 Sites)

Clinical Trials

Genentech, Inc.

Image of Retinal Consultants of AZ, Ltd in Peoria, United States.

RO7497372 for Diabetic Macular Edema

18+
All Sexes
Peoria, AZ

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

Phase 1
Waitlist Available

Retinal Consultants of AZ, Ltd (+36 Sites)

Clinical Trials

Genentech, Inc.

Have you considered Derma-Smoothe/Fs clinical trials?

We made a collection of clinical trials featuring Derma-Smoothe/Fs, we think they might fit your search criteria.
Go to Trials
Image of University of Virginia in Charlottesville, United States.

Methadone vs Remifentanil for Pain in Craniotomy Surgery

18 - 65
All Sexes
Charlottesville, VA

Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.

Phase < 1
Waitlist Available

University of Virginia

Image of Scottsdale, Arizona in Scottsdale, United States.

EYE201 for Eye Conditions

18+
All Sexes
Scottsdale, AZ

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.

Phase 1 & 2
Recruiting

Scottsdale, Arizona (+25 Sites)

EyeBiotech Ltd.

Have you considered Derma-Smoothe/Fs clinical trials?

We made a collection of clinical trials featuring Derma-Smoothe/Fs, we think they might fit your search criteria.
Go to Trials